Celltrion to retire 400 mn treasury stock in January - Korea Economic Daily
| 068760 Stock | KRW 59,800 1,300 2.13% |
About 62% of Celltrion Pharm's investor base is looking to short. The analysis of current outlook of investing in Celltrion Pharm suggests that many traders are alarmed regarding Celltrion Pharm's prospects. The current market sentiment, together with Celltrion Pharm's historical and current headlines, can help investors time the market. In addition, many technical investors use Celltrion Pharm stock news signals to limit their universe of possible portfolio assets.
Celltrion |
Celltrion to retire 400 mn treasury stock in January Korea Economic Daily
Read at news.google.com
 |
Celltrion Pharm Fundamental Analysis
We analyze Celltrion Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celltrion Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celltrion Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Celltrion Pharm is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Celltrion Pharm Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Celltrion Pharm stock to make a market-neutral strategy. Peer analysis of Celltrion Pharm could also be used in its relative valuation, which is a method of valuing Celltrion Pharm by comparing valuation metrics with similar companies.
Peers
Celltrion Pharm Related Equities
| 039840 | DIO | 0.55 |
| ||
| 086900 | Medy Tox | 0.72 |
| ||
| 041830 | InBody CoLtd | 2.29 |
| ||
| 036830 | Soulbrain Holdings | 5.00 |
|
Complementary Tools for Celltrion Stock analysis
When running Celltrion Pharm's price analysis, check to measure Celltrion Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celltrion Pharm is operating at the current time. Most of Celltrion Pharm's value examination focuses on studying past and present price action to predict the probability of Celltrion Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celltrion Pharm's price. Additionally, you may evaluate how the addition of Celltrion Pharm to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |